CGP 40215A

Drug Profile

CGP 40215A

Latest Information Update: 30 May 2001

Price : $50

At a glance

  • Originator Novartis
  • Class Antiprotozoals; Guanidines
  • Mechanism of Action Adenosylmethionine decarboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Malaria
  • Discontinued Pneumocystis pneumonia

Most Recent Events

  • 30 May 2001 Profile reviewed but no significant changes made
  • 30 Jul 1998 No-Development-Reported for Cancer in Switzerland (Unknown route)
  • 30 Jul 1998 No-Development-Reported for Malaria in Israel (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top